STVN — Stevanato Group S.p.A.

Summary of Stevanato Group (STVN) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: €346.5 million, up 7% at constant currency and 5% reported.
• Full Year 2025 Revenue: Increased by 9% at constant currency and 7% reported compared to 2024.
• Gross Profit Margin: Improved by 120 basis points to 30.9% in Q4 2025.
• Operating Profit Margin: 20.2% for Q4; adjusted EBITDA margin rose to 28.2%.
• Net Profit: €47.6 million for Q4; adjusted net profit was €49.8 million.
• Earnings Per Share: Diluted EPS of €0.17; adjusted diluted EPS of €0.18.
• Full Year Free Cash Flow: Positive at €18.4 million, with cash from operations totaling €286.1 million.

2. Strategic Updates and Business Highlights

• The Biopharmaceutical and Diagnostic Solutions (BDS) segment saw double-digit growth, driven by high-value solutions, which accounted for 46% of total revenue.
• The Nexa syringe was highlighted as the fastest-growing product, particularly benefiting from the rising demand for GLP-1 treatments, which contributed approximately 19-20% of total revenue.
• Investments in capacity expansion in Fishers, Indiana, and Latin Italy are ongoing to meet demand for high-value syringes and EZ-fill cartridges.
• The company is pivoting away from non-high-value product categories to focus on premium offerings aligned with strategic goals.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to range between €1.260 billion and €1.290 billion, with adjusted EBITDA between €331.8 million and €346.9 million.
• Anticipated growth for GLP-1s in 2026 is projected in the mid-teens percentage range.
• The BDS segment is expected to grow in the high single to low double digits, while the Engineering segment is forecasted to decline by mid-single to low double digits.
• Capital expenditures are projected between €270 million and €290 million, with expectations for breakeven to positive free cash flow of approximately €20 million.

4. Bad News, Challenges, or Points of Concern

• The Engineering segment experienced a revenue decline of 23% in Q4 due to lower order intake, which is expected to continue into 2026.
• There are headwinds from foreign currency translation, estimated at €18 million for 2026, with an impact of approximately €10 million in Q1.
• The sales cycle for new orders in the Engineering segment is taking longer than anticipated, leading to a more cautious outlook.
• The company is facing challenges in converting opportunities into firm orders, indicating potential competitive pressures.

5. Notable Q&A Insights

• Management expressed confidence in the continued demand for GLP-1s but acknowledged a normalization of growth rates after a strong 2025.
• The company is optimistic about the long-term growth outlook for biologics, particularly in the injectable market, with a strong pipeline of products.
• Discussions revealed that the transition to new formats (e.g., cartridges) is ongoing, but syringes will continue to dominate the GLP-1 market in the near term.
• There is a strategic focus on high-value products, with plans to divest from non-aligned categories to enhance profitability and market position.
• Management highlighted the importance of operational improvements and customer validations in both Fishers and Latina facilities as key to future growth.

Overall, Stevanato Group reported solid financial performance in 2025, driven by high-value solutions, while navigating challenges in the Engineering segment and foreign currency impacts. The company remains focused on strategic growth in biologics and high-value products as it looks ahead to 2026.